AZELNIDIPINE COMBINED WITH ANGIOTENSIN RECEPTOR BLOCKER CAN RESTORE SYMPATHETIC ACTIVITY
Phase of Trial: Phase IV
Latest Information Update: 19 Oct 2016
At a glance
- Drugs Azelnidipine (Primary) ; Olmesartan medoxomil (Primary)
- Indications Kidney disorders
- Focus Therapeutic Use
- 16 Oct 2016 Status changed from active, no longer recruiting to completed.
- 05 Aug 2015 Planned End Date changed from 31 Dec 2013 to 31 May 2014 as reported by University Hospital Medical Information Network - Japan.
- 05 Aug 2015 Status changed from recruiting to active, no longer recruiting as reported by University Hospital Medical Information Network - Japan.